Therapy of allergic bronchial asthma with omalizumab - An anti-IgE monoclonal antibody

Expert Opinion on Biological Therapy

Volumn 3, Issue 2, 2003, Pages 371-376

  D'Amato, Gennaro ^a,b  

^a CARDARELLI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Allergic asthma; Allergic respiratory diseases; Allergy treatment with anti IgE; Anti IgE antibodies; Bronchial asthma; Omalizumab; Respiratory allergy

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB;

ALLERGIC ASTHMA; ALLERGIC REACTION; ALLERGIC RHINITIS; ANTIGEN ANTIBODY COMPLEX; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; HUMAN; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SIDE EFFECT;

MURINAE;

EID: 0037393377     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.2.371     Document Type: Review

References (29)

1. EUROPEAN COMMUNITY RESPIRATORY HEALTH SURVEY: Variations in the prevalence of respiratory symptoms, self-reported asthma attacks and the use of asthma medications in the European Community Respiratory Health Survey (ECRHS). Eur. Respir. J. (1996) 9:687-695.
2. WOOLCOCK AJ, PEAT JK: Evidence for the increase in asthma worldwide. In: The rising trend in asthma. Ciba Foundation Symposium 206, John Wiley & Sons, Chichester (1997):122-139.
3. THE INTERNATIONAL STUDY OF ASTHMA AND ALLERGY IN CHILDHOOD (ISAAC) STEERING COMMITTEE: Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema. Lancet (1998) 351:1225-1232.
4. HOLGATE ST: The cellular and mediator basis of asthma in relation to natural history. Lancet (1997) 350(Suppl. II):5-9.
5. D'AMATO G, HOLGATE ST: The impact of air pollution on respiratory health. D'Amato G & Holgate ST (Eds), European Respiratory Monograph n.21, Sheffield, UK (2002).
6. BOUSQUET J, CHANEZ P, LACOSTE JY et al.: Eosinophilic inflammation in asthma. N. Engl. J. Med (1990) 323:1033-1039.
7. BUSSE WW, COFFMAN RL, GELFAND EW, KAY AB, ROSENWASSER LJ: Mechanisms of persistent airway inflammation in asthma. A role for T cells and T-cell products. Am. J. Respir. Crit. Care Med. (1995) 152:388-393.
8. PRESTA LG, LAHR SJ, SHIELDS RL et al.: Humanization of an antibody directed against IgE. J. Immunol. (1993) 151:2623-2632.
9. LIU J, LESTER P, BUILDER S, SHIRE SJ: Characterization of complex formation by humanized anti-IgE antibody and monoclonal IgE. Biochemistry (1995) 34:10474-10482.
10. MACGLASHAN DW, BOCHNER BS, ADELMAN DC et al: Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. (1997) 158:1438-1445.
11. BOULET L-P, CHAPMAN KR, COTE J et al.: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am. J. Respir. Crit. Care Med. (1997) 155:1835-1840.
12. FAHY JV, FLEMING HE, WONG HH et al.: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. (1997) 155:1828-1834.
13. CASALE TB, BERNSTEIN IL, BUSSE WW et al: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol. (1997) 100:110-121.
14. TOGIAS A, CORREN J, SHAPIRO G et al.: Anti-IgE treatment reduces skin test (ST) reactivity. J. Allergy Clin. Immunol. (1998) 101:S171.
15. CASALE T, CONDEMI J, MILLER SD et al.: rhuMAb-E25 in the treatment of seasonal allergic rhinitis (SAR). Ann. Allergy Asthma Immunol. (1999) 82:75.
16. ADELROTH E, RAK S, HAAHTELA T et al: Recombinant humanized mAb E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2000) 106(2):253-259.
17. FAHY JV: The anti-IgE treatment strategy for asthma. In: New and Exploratory Therapeutic Agents for Asthma: Lung Biology in Health and Disease, Yeadon M, Diamant Z (Eds), Marcel Dekker, Inc., NY (2000):329-342.
18. BUHL R, SOLER M, MATZ J et al.: Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur. Respir. J. (2002) 20:73-78.
19. BUHL R, HANF G, SOLER M et al.: The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur. Respir. J. (2002) 20:1088-1094.
20. HOLGATE S, BOUSQUET J, WENZEL S, FOX H, LIU J, CASTELLSAGUE J: Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr. Med. Res. Opin. (2001) 17:233-240.
21. MILGROM H, BERGER W, NAYAK A et al.: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics (2001) 108(2):36-45.
22. SOLER M, MATZ J, TOWNLEY R et al.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. (2001) 18:254-261.
23. BUSSE W, COREN J, LANIER BQ et al.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. (2001) 108:184-190.
24. D'AMATO G: Treating atopic asthma with the anti-IgE monoclonal antibody. Monaldi Arch. Chest Dis. (2002) 57(2):117-119.
25. PLEWAKO H, ARVIDSSON M, PETRUSON K et al.: The effect of omalizumab on nasal allergic inflammation. J. Allergy Clin. Immunol. (2002) 110:68-71.
26. KUEHR J, BRAUBURGER J, ZIELEN S et al.: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2002) 109:274-280.
27. KOPP MV, BRAUBURGER J, RIEDINGER F et al.: The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2002) 110:728-735.
28. ISHIZAKA K, ISHIZAKA T: Physicochemical properties of reaginic antibodies. I. Association of reaginic activity with an immunoglobulin other than gamma A or gamma G globulin. J. Allergy (1966) 37:169-173.
29. JOHANSSON SGO, BENNICH H: Immunological studies of an atypical (myeloma) immunoglobulin. Immunology (1967) 13:381-384.